JP2013514074A - 癌の診断および処置 - Google Patents

癌の診断および処置 Download PDF

Info

Publication number
JP2013514074A
JP2013514074A JP2012543894A JP2012543894A JP2013514074A JP 2013514074 A JP2013514074 A JP 2013514074A JP 2012543894 A JP2012543894 A JP 2012543894A JP 2012543894 A JP2012543894 A JP 2012543894A JP 2013514074 A JP2013514074 A JP 2013514074A
Authority
JP
Japan
Prior art keywords
cancer
prelp
omd
target protein
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012543894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514074A5 (cg-RX-API-DMAC7.html
Inventor
信一 大沼
ジョン ダニエル ケリー
隆二 浜本
ジュリー ワトソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2013514074A publication Critical patent/JP2013514074A/ja
Publication of JP2013514074A5 publication Critical patent/JP2013514074A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012543894A 2009-12-17 2010-12-17 癌の診断および処置 Pending JP2013514074A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0922085.6 2009-12-17
GBGB0922085.6A GB0922085D0 (en) 2009-12-17 2009-12-17 Cancer diagnosis and treatment
PCT/GB2010/002294 WO2011073629A2 (en) 2009-12-17 2010-12-17 Cancer diagnosis and treatment

Publications (2)

Publication Number Publication Date
JP2013514074A true JP2013514074A (ja) 2013-04-25
JP2013514074A5 JP2013514074A5 (cg-RX-API-DMAC7.html) 2014-02-13

Family

ID=41717134

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012543894A Pending JP2013514074A (ja) 2009-12-17 2010-12-17 癌の診断および処置

Country Status (5)

Country Link
US (1) US20120304318A1 (cg-RX-API-DMAC7.html)
EP (1) EP2512601A2 (cg-RX-API-DMAC7.html)
JP (1) JP2013514074A (cg-RX-API-DMAC7.html)
GB (1) GB0922085D0 (cg-RX-API-DMAC7.html)
WO (1) WO2011073629A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021128140A (ja) * 2020-06-30 2021-09-02 株式会社ヤマト 漏水監視システム

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20110136683A1 (en) 2008-05-28 2011-06-09 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
KR101445560B1 (ko) 2012-05-10 2014-09-29 한국수력원자력 주식회사 저준위 전리방사선에 민감한 유전자 검출 방법 및 상기 방법으로 검출된 유전자
KR101416147B1 (ko) * 2012-07-18 2014-07-09 국립암센터 위암 진단 및 치료를 위한 ａｄｃｙ3의 용도
EP3435084B1 (en) 2012-08-16 2023-02-22 Decipher Biosciences, Inc. Prostate cancer prognostics using biomarkers
EP2971174A4 (en) * 2013-03-14 2017-06-14 Genomedx Biosciences Inc. Cancer biomarkers and classifiers and uses thereof
CN110139656A (zh) 2016-08-05 2019-08-16 纽约州州立大学研究基金会 作为膀胱癌的生物标志物的角蛋白17
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
CA3050984A1 (en) 2017-01-20 2018-07-26 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
EP3622087A4 (en) 2017-05-12 2021-06-16 Decipher Biosciences, Inc. GENETIC SIGNATURES FOR PREDICTING PROSTATE CANCER METASTASIS AND IDENTIFYING TUMOR VIRULENCE
EP4428157A3 (en) 2017-08-04 2024-12-11 Veracyte SD, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
CN113957152A (zh) * 2021-12-14 2022-01-21 浙江大学 一种snhg6基因的检测试剂盒及其应用
CN114592007B (zh) * 2022-04-29 2023-10-27 昆明理工大学 Far1基因的新用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024283A2 (de) * 2004-08-31 2006-03-09 Technische Universität Dresden Verbindungen und methoden zur behandlung, diagnose und prognose bei pankreaserkrankungen
JP2008532477A (ja) * 2005-02-10 2008-08-21 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
JP2009034092A (ja) * 2007-08-01 2009-02-19 National Yang Ming Univ グリシンメチルトランスフェラーゼ（ｇｎｍｔ）動物モデル及びその使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
JP2775346B2 (ja) 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド プローブ構成物および方法
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
FI954316L (fi) 1993-03-15 1995-11-03 Cell Genesys Inc Menetelmä DNA-vajauksen määrittämiseksi
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
US5552277A (en) 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
AU2253397A (en) 1996-01-23 1997-08-20 Affymetrix, Inc. Nucleic acid analysis techniques
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
JP2003524599A (ja) * 1998-09-14 2003-08-19 ジェネンテック・インコーポレーテッド 血管新生と心血管新生の促進又は阻害
WO2004009033A2 (en) * 2002-07-24 2004-01-29 Schering Corporation Methods of modulating proliferative conditions
GB0224436D0 (en) 2002-10-21 2002-11-27 Univ Cambridge Tech Polypetides methods and means
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1904645B1 (en) * 2005-07-08 2010-08-04 Siemens Healthcare Diagnostics GmbH Method for predicting and monitoring direct response to cancer therapy
EP1991274A4 (en) * 2006-01-20 2009-06-10 Women S And Children S Health METHOD OF TREATMENT, PROPHYLAXIS AND DIAGNOSIS OF BONE PATHOLOGIES
WO2007142347A1 (ja) 2006-06-05 2007-12-13 Shimadzu Corporation 腫瘍マーカー及び癌疾病の罹患の識別方法
AT504702A1 (de) * 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024283A2 (de) * 2004-08-31 2006-03-09 Technische Universität Dresden Verbindungen und methoden zur behandlung, diagnose und prognose bei pankreaserkrankungen
JP2008532477A (ja) * 2005-02-10 2008-08-21 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
JP2009034092A (ja) * 2007-08-01 2009-02-19 National Yang Ming Univ グリシンメチルトランスフェラーゼ（ｇｎｍｔ）動物モデル及びその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021128140A (ja) * 2020-06-30 2021-09-02 株式会社ヤマト 漏水監視システム

Also Published As

Publication number Publication date
GB0922085D0 (en) 2010-02-03
EP2512601A2 (en) 2012-10-24
WO2011073629A2 (en) 2011-06-23
US20120304318A1 (en) 2012-11-29
WO2011073629A3 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
JP2013514074A (ja) 癌の診断および処置
JP6383743B2 (ja) Ｅｒｇ遺伝子発現における前立腺癌特異的変化ならびにそれらの変化に基づく検出および治療方法
JP6404378B2 (ja) 前立腺癌における再発性遺伝子融合
EP1814909B1 (en) Use of aimp2dx2 for the diagnosis and treatment of cancer
JP6048660B2 (ja) 甲状腺癌を診断および処置するための方法および組成物
US7799518B2 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20110104062A1 (en) Biomarkers for Head-And-Neck Cancers and Precancers
US8007995B2 (en) Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
CN102812130A (zh) 前列腺癌中的复现性基因融合体
WO2002071928A2 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
Watanabe et al. Activation of PI3K-AKT pathway in oral epithelial dysplasia and early cancer of tongue
US20030224399A1 (en) Methods for determining the prognosis for patients with a prostate neoplastic condition
EP1326996A1 (en) Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
CA2687997A1 (en) Diagnostic methods and markers
CN101087804B (zh) 用于诊断和治疗癌症的aimp2dx2的用途
US9789159B2 (en) Diagnosis and treatment of prostate cancer
De Muga et al. CXCR4 mRNA overexpression in high grade prostate tumors: Lack of association with TMPRSS2-ERG rearrangement
JP2007532889A (ja) 癌の進行度をモニタリングする方法
JP4256169B2 (ja) Ｔｕｃａｎを用いて癌患者の予後を決定するための方法
JP2008507976A (ja) マイクロサテライト不安定性における遺伝子の発現の差次的発現
Ho et al. BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women
Tse Screening of Potential Ductal Carcinoma in Situ (DCIS) Marker in Asian Women
FACTOR-ß-REFRACTORY SMAD PROTEIN EXPRESSION AND ACTIVATION IN TRANSFORMING GROWTH
WOLF et al. Oral Communication: Neuro/Endocrinopathology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151110